Literature DB >> 16231009

Activity of recombinant trypsin isoforms on human proteinase-activated receptors (PAR): mesotrypsin cannot activate epithelial PAR-1, -2, but weakly activates brain PAR-1.

Zoryana Grishina1, Ewa Ostrowska, Walter Halangk, Miklós Sahin-Tóth, Georg Reiser.   

Abstract

Trypsin-like serine proteinases trigger signal transduction pathways through proteolytic cleavage of proteinase-activated receptors (PARs) in many tissues. Three members, PAR-1, PAR-2 and PAR-4, are trypsin substrates, as trypsinolytic cleavage of the extracellular N terminus produces receptor activation. Here, the ability of the three human pancreatic trypsin isoforms (cationic trypsin, anionic trypsin and mesotrypsin (trypsin IV)) as recombinant proteins was tested on PARs. Using fura 2 [Ca(2+)](i) measurements, we analyzed three human epithelial cell lines, HBE (human bronchial epithelial), A549 (human pulmonary epithelial) and HEK (human embryonic kidney)-293 cells, which express functional PAR-1 and PAR-2. Human mesotrypsin failed to induce a PAR-mediated Ca(2+) response in human epithelial cells even at high concentrations. In addition, mesotrypsin did not affect the magnitude of PAR activation by subsequently added bovine trypsin. In HBE cells, which like A549 cells express high PAR-2 levels with negligible PAR-1 levels (<11%), half-maximal responses were seen for both cationic and anionic trypsins at about 5 nM. In the epithelial cells, mesotrypsin did not activate PAR-2 or PAR-1, whereas both anionic and cationic trypsins were comparable activators. We also investigated human astrocytoma 1321N1cells, which express PAR-1 and some PAR-3, but no PAR-2. High concentrations (>100 nM) of mesotrypsin produced a relatively weak Ca(2+) signal, apparently through PAR-1 activation. Half-maximal responses were observed at 60 nM mesotrypsin, and at 10-20 nM cationic and anionic trypsins. Using a desensitization assay with PAR-2-AP, we confirmed that both cationic and anionic trypsin isoforms cause [Ca(2+)](i) elevation in HBE cells mainly through PAR-2 activation. Desensitization of PAR-1 with thrombin receptor agonist peptide in 1321N1 cells demonstrated that all three recombinant trypsin isoforms act through PAR-1.Thus, the activity of human cationic and anionic trypsins on PARs was comparable to that of bovine pancreatic trypsin. Mesotrypsin (trypsin IV), in contrast to cationic and anionic trypsin, cannot activate or disable PARs in human epithelial cells, demonstrating that the receptors are no substrates for this isoenzyme. On the other hand, mesotrypsin activates PAR-1 in human astrocytoma cells. This might play a role in protection/degeneration or plasticity processes in the human brain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16231009      PMCID: PMC1751236          DOI: 10.1038/sj.bjp.0706410

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

Review 1.  Protease-activated receptors: contribution to physiology and disease.

Authors:  Valeria S Ossovskaya; Nigel W Bunnett
Journal:  Physiol Rev       Date:  2004-04       Impact factor: 37.312

Review 2.  Proteinase-activated receptors: novel signals for peripheral nerves.

Authors:  Nathalie Vergnolle; Mara Ferazzini; Michael R D'Andrea; Jörg Buddenkotte; Martin Steinhoff
Journal:  Trends Neurosci       Date:  2003-09       Impact factor: 13.837

3.  Crystal structure reveals basis for the inhibitor resistance of human brain trypsin.

Authors:  Gergely Katona; Gunnar I Berglund; Janos Hajdu; László Gráf; László Szilágyi
Journal:  J Mol Biol       Date:  2002-02-01       Impact factor: 5.469

Review 4.  Thrombin signaling in the brain: the role of protease-activated receptors.

Authors:  Hong Wang; Georg Reiser
Journal:  Biol Chem       Date:  2003-02       Impact factor: 3.915

5.  Human bronchial epithelial cells express PAR-2 with different sensitivity to thermolysin.

Authors:  Joachim J Ubl; Zoryana V Grishina; Tatiana K Sukhomlin; Tobias Welte; Fariba Sedehizade; Georg Reiser
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-06       Impact factor: 5.464

6.  Human anionic trypsinogen: properties of autocatalytic activation and degradation and implications in pancreatic diseases.

Authors:  Zoltán Kukor; Miklós Tóth; Miklós Sahin-Tóth
Journal:  Eur J Biochem       Date:  2003-05

7.  Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases.

Authors:  Sophie Dulon; Céline Candé; Nigel W Bunnett; Morley D Hollenberg; Michel Chignard; Dominique Pidard
Journal:  Am J Respir Cell Mol Biol       Date:  2003-03       Impact factor: 6.914

8.  Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes.

Authors:  Candice E Junge; C Justin Lee; Katherine B Hubbard; Zhoabin Zhang; Jeffrey J Olson; John R Hepler; Daniel J Brat; Stephen F Traynelis
Journal:  Exp Neurol       Date:  2004-07       Impact factor: 5.330

9.  Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors.

Authors:  Richárd Szmola; Zoltán Kukor; Miklos Sahin-Tóth
Journal:  J Biol Chem       Date:  2003-09-24       Impact factor: 5.157

10.  Trypsin IV, a novel agonist of protease-activated receptors 2 and 4.

Authors:  Graeme S Cottrell; Silvia Amadesi; Eileen F Grady; Nigel W Bunnett
Journal:  J Biol Chem       Date:  2004-01-15       Impact factor: 5.157

View more
  18 in total

1.  Human mesotrypsin exhibits restricted S1' subsite specificity with a strong preference for small polar side chains.

Authors:  Edit Szepessy; Miklós Sahin-Tóth
Journal:  FEBS J       Date:  2006-06-05       Impact factor: 5.542

Review 2.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

Review 3.  Biochemical and structural insights into mesotrypsin: an unusual human trypsin.

Authors:  Moh'd A Salameh; Evette S Radisky
Journal:  Int J Biochem Mol Biol       Date:  2013-09-13

4.  The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin.

Authors:  Moh'd A Salameh; Jessica L Robinson; Duraiswamy Navaneetham; Dipali Sinha; Benjamin J Madden; Peter N Walsh; Evette S Radisky
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

5.  Fluvastatin inhibits Rab5-mediated IKs internalization caused by chronic Ca2+-dependent PKC activation.

Authors:  Xiaorong Xu Parks; Elsa Ronzier; Jin O-Uchi; Coeli M Lopes
Journal:  J Mol Cell Cardiol       Date:  2019-03-18       Impact factor: 5.000

6.  Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma.

Authors:  Bonan Lin; Xiaomeng Zhou; Shuye Lin; Xiaoyue Wang; Meiying Zhang; Baoping Cao; Yan Dong; Shuai Yang; Ji Ming Wang; Mingzhou Guo; Jiaqiang Huang
Journal:  J Mol Med (Berl)       Date:  2017-08-26       Impact factor: 4.599

7.  Presence versus absence of hydrogen bond donor Tyr-39 influences interactions of cationic trypsin and mesotrypsin with protein protease inhibitors.

Authors:  Moh'd A Salameh; Alexei S Soares; Alexandre Alloy; Evette S Radisky
Journal:  Protein Sci       Date:  2012-06-25       Impact factor: 6.725

8.  Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin.

Authors:  Moh'd A Salameh; Alexei S Soares; Duraiswamy Navaneetham; Dipali Sinha; Peter N Walsh; Evette S Radisky
Journal:  J Biol Chem       Date:  2010-09-22       Impact factor: 5.157

9.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

10.  Serine proteases and protease-activated receptor 2 mediate the proinflammatory and algesic actions of diverse stimulants.

Authors:  F Cattaruzza; S Amadesi; J F Carlsson; J E Murphy; V Lyo; K Kirkwood; G S Cottrell; M Bogyo; W Knecht; N W Bunnett
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.